Last updated: August 15, 2026
Kimyrsa is a lyophilized, single-dose intravenous formulation of oritavancin approved for acute bacterial skin and skin structure infections. Its excipient strategy is commercially important because the product requires reconstitution with Sterile Water for Injection, dilution in 5% Dextrose Injection, and administration over one hour. The formulation creates opportunities in hospital-ready preparation, compatible diluents, infusion workflow, packaging, and follow-on formulation development.
What is the Kimyrsa formulation?
Kimyrsa contains oritavancin, mannitol, phosphoric acid, and sodium hydroxide. The product is supplied as a sterile lyophilized powder in a single-dose vial. The label identifies mannitol as a bulking or stabilizing excipient and phosphoric acid and sodium hydroxide as pH-adjusting components. The label does not disclose the quantitative composition of each inactive ingredient.[1]
Kimyrsa formulation profile
| Attribute |
Kimyrsa specification |
| Active ingredient |
Oritavancin |
| Dosage form |
Lyophilized powder for solution |
| Dose |
1,200 mg intravenously once |
| Vial type |
Single-dose vial |
| Reconstitution diluent |
Sterile Water for Injection |
| Required final diluent |
5% Dextrose Injection |
| Administration time |
Approximately one hour |
| Listed excipients |
Mannitol, phosphoric acid, sodium hydroxide |
| Approved indication |
Acute bacterial skin and skin structure infections |
| FDA approval |
March 12, 2021 |
| NDA |
214429 |
The single-dose presentation reduces repeated dosing and outpatient treatment complexity compared with multi-day intravenous antibiotic regimens. The excipient system must support physical stability during lyophilization, reconstitution, dilution, and one-hour infusion.
Why does the Kimyrsa diluent restriction matter commercially?
Kimyrsa must be diluted in 5% Dextrose Injection. The prescribing information directs users not to use saline-containing solutions because of compatibility concerns.[1] This restriction affects pharmacy preparation, inventory management, infusion-center protocols, and emergency-department workflows.
Most hospital intravenous products can be prepared with normal saline or dextrose. Kimyrsa's more limited compatibility profile creates several commercial consequences:
- Hospitals must maintain access to 5% Dextrose Injection.
- Pharmacy systems must encode a product-specific preparation instruction.
- Nurses and infusion centers must avoid inadvertent saline dilution.
- Premixed or ready-to-use delivery systems must preserve dextrose compatibility.
- Any alternative formulation must demonstrate compatibility with commonly used diluents without compromising oritavancin stability.
The commercial opportunity is strongest in reducing preparation errors and shortening pharmacy handling time. A ready-to-administer presentation in a validated dextrose vehicle could improve operational value, although it would require substantial stability, container-closure, extractables, leachables, and regulatory work.
What excipients are protected by the Kimyrsa formulation?
The public FDA label identifies the excipients but does not establish whether a particular excipient combination is protected by an issued patent. Patent protection may arise from claims covering:
- Oritavancin lyophilized compositions.
- Mannitol-containing formulations.
- Buffer or pH-control systems.
- Reconstitution and dilution conditions.
- Concentration ranges.
- Stability during storage or infusion.
- Container-closure systems.
- Manufacturing processes.
- Reduced infusion-time formulations.
An excipient is not independently patent-protected merely because it appears in the approved product. Protection depends on the wording, validity, enforceability, and expiration of the relevant patent claims.
What patents protect Kimyrsa?
The FDA prescribing information and approval letter do not identify the complete patent estate. A reliable patent assessment must distinguish between Orange Book-listed patents, unlisted formulation patents, manufacturing patents, continuation applications, and patents that cover related oritavancin products rather than Kimyrsa specifically.
The principal diligence questions are:
| Issue |
Commercial relevance |
| Orange Book listing |
Determines potential generic patent certification requirements |
| Formulation claims |
May restrict lyophilized or ready-to-use alternatives |
| Process claims |
Can affect contract manufacturing and scale-up |
| Method-of-use claims |
May affect labeling and indication-specific entry |
| Continuation patents |
Can extend prosecution activity after the original grant |
| Patent expiration |
Determines the timing of non-infringing entry |
| Litigation history |
Shows whether the sponsor has enforced formulation or use claims |
No conclusion should be drawn from the presence of mannitol, phosphoric acid, or sodium hydroxide alone. Generic or alternative-product developers would need to conduct claim-level analysis rather than rely on ingredient matching.
How does Kimyrsa's excipient strategy compare with Orbactiv?
Kimyrsa and Orbactiv contain the same active moiety, oritavancin, but use different administration workflows. Orbactiv is administered as a 1,200 mg intravenous dose over approximately three hours. Kimyrsa is administered over approximately one hour.[1,2]
| Product |
Active ingredient |
Dose |
Infusion time |
Commercial formulation distinction |
| Orbactiv |
Oritavancin |
1,200 mg once |
Approximately 3 hours |
Earlier oritavancin IV presentation |
| Kimyrsa |
Oritavancin |
1,200 mg once |
Approximately 1 hour |
Faster infusion-oriented formulation |
The shorter infusion time is the main practical differentiation. The value of the Kimyrsa formulation therefore depends less on the identity of the excipients than on the complete formulation-performance package: reconstitution time, dilution compatibility, infusion duration, stability, and hospital usability.
A competing product using the same active ingredient would need to assess whether it can offer a meaningful improvement in one or more of these attributes without infringing formulation or process claims.
What commercial opportunities exist for Kimyrsa excipients?
Hospital-ready dextrose presentations
A pharmacy-ready Kimyrsa presentation could eliminate several preparation steps. Potential formats include:
- A vial with an integrated transfer device.
- A dual-chamber container holding drug and dextrose separately.
- A manufacturer-prepared bag with validated refrigerated or room-temperature stability.
- A pharmacy compounding kit containing the vial, Sterile Water for Injection, and compatible dextrose diluent.
The strongest opportunity is workflow simplification. The product's current preparation sequence requires reconstitution followed by transfer and dilution. Any commercial format that reduces manipulation could lower preparation time and contamination risk.
Compatible infusion containers and administration sets
Because Kimyrsa is restricted to 5% Dextrose Injection, container and administration-set compatibility has commercial relevance. Suppliers could develop validated packaging combinations involving:
- Non-PVC or low-sorbing infusion bags.
- Tubing sets with demonstrated oritavancin compatibility.
- Closed-system transfer devices.
- Standardized one-hour infusion kits.
- Barcode-enabled preparation components.
These products would not replace the approved drug. They could support hospital use, provided their labeling and compatibility claims remain within applicable regulatory boundaries.
Stability-enhancing formulation work
Future formulation research could target:
- Longer post-reconstitution stability.
- Room-temperature storage after dilution.
- Reduced sensitivity to dilution conditions.
- Lower reconstitution volume.
- Faster dissolution of the lyophilized cake.
- Compatibility with normal saline or balanced crystalloid solutions.
- Reduced particulate formation.
- Smaller final infusion volume.
The highest-value development target is broader diluent compatibility. Normal saline is widely stocked in hospitals, while a dextrose-only requirement creates operational friction. A formulation that permits both dextrose and saline could improve adoption, but such a change would require new clinical, pharmaceutical, and regulatory support.
What manufacturing and IP barriers affect follow-on Kimyrsa products?
Kimyrsa is a complex sterile injectable rather than a conventional tablet. Development barriers include:
- Reproducing the lyophilized cake and reconstitution behavior.
- Matching impurity and degradation profiles.
- Demonstrating sterility assurance.
- Controlling particulate matter.
- Establishing container-closure integrity.
- Characterizing drug-excipient interactions.
- Demonstrating in-use stability during the one-hour infusion.
- Validating compatibility with the specified bag and administration set.
- Establishing bioequivalence or other applicable approval requirements.
Oritavancin is a large glycopeptide antibiotic with complex structural and analytical attributes. A follow-on product may face more technical risk than a conventional small-molecule injectable, even if the active ingredient is chemically defined.
The excipient system can also create manufacturing constraints. Mannitol affects cake structure and collapse behavior during lyophilization. Buffer and pH controls can influence degradation, solubility, and particulate generation. The commercial developer must optimize the entire process rather than substitute excipients in isolation.
What is the FDA regulatory status of Kimyrsa?
The FDA approved Kimyrsa under NDA 214429 on March 12, 2021, for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.[3] The approved regimen is a single 1,200 mg intravenous dose infused over approximately one hour.[1]
Kimyrsa is not a biologic, so biosimilar approval provisions do not apply. A competing product would generally be evaluated through an abbreviated or full drug application pathway depending on the product's formulation, equivalence profile, and regulatory strategy.
A materially different formulation, such as a ready-to-use solution or a saline-compatible product, could require more extensive pharmaceutical and clinical support than a conventional generic copy of the approved lyophilized presentation.
When does Kimyrsa lose exclusivity?
Kimyrsa's commercial exclusivity cannot be determined from FDA approval date alone. Oritavancin was previously approved in Orbactiv, so Kimyrsa did not originate the active moiety. The relevant exclusivity analysis must separate:
- Product-specific FDA exclusivity.
- Orange Book-listed patents.
- Formulation patents.
- Manufacturing patents.
- Method-of-use patents.
- Litigation-based entry restrictions.
- Regulatory exclusivity associated with any later-approved indication.
The March 12, 2021 approval date is a regulatory milestone, not necessarily the date of final generic or formulation entry. Patent and exclusivity conclusions should be based on current FDA Orange Book records and issued patent claims rather than the Kimyrsa label alone.[4]
What generic entry risks exist for Kimyrsa?
The greatest generic-entry risk is likely to come from a product that replicates the approved lyophilized presentation while designing around any formulation claims. A second pathway involves a differentiated product with:
- Faster reconstitution.
- Broader diluent compatibility.
- Longer post-dilution stability.
- A ready-to-use presentation.
- Lower preparation burden.
- More convenient infusion packaging.
Paragraph IV litigation risk would depend on the patents listed for the reference product and the certifications made by an ANDA applicant. The absence of a publicly identified patent in the label does not establish freedom to launch.
For investors and licensing teams, the key exposure is not only patent expiration. It is whether a competing injectable can achieve pharmaceutical equivalence, manufacturing scale, and hospital acceptance at a cost that supports launch.
Which companies could capture Kimyrsa-related opportunities?
The commercial field includes several categories of participants:
| Participant type |
Opportunity |
| Generic injectable manufacturers |
Develop an ANDA or alternative sterile injectable |
| Contract development organizations |
Lyophilization, analytical development, and sterile manufacturing |
| Infusion-device companies |
Closed transfer, tubing, and ready-to-administer systems |
| Dextrose and IV-fluid suppliers |
Compatible premixed diluent presentations |
| Hospital-pharmacy technology firms |
Preparation instructions, barcoding, and workflow controls |
| Specialty pharmaceutical companies |
Licensing or acquiring differentiated oritavancin formulations |
| Packaging companies |
Dual-chamber and integrated reconstitution systems |
The most defensible licensing opportunities are likely to involve validated delivery systems, stability improvements, and manufacturing know-how. A simple excipient substitution would have weaker commercial differentiation unless it produces a measurable improvement in stability, compatibility, or administration.
Key Takeaways
- Kimyrsa is a single-dose, lyophilized oritavancin product containing mannitol, phosphoric acid, and sodium hydroxide.
- Its principal operational limitation is the requirement for dilution in 5% Dextrose Injection rather than saline.
- The most attractive commercial opportunities involve ready-to-administer packaging, closed-system preparation, infusion-set compatibility, and broader diluent compatibility.
- Kimyrsa is differentiated from Orbactiv primarily by its approximately one-hour infusion time.
- Excipients alone do not establish patent protection. The relevant analysis requires claim-level review of formulation, process, use, and Orange Book-listed patents.
- Kimyrsa is a small-molecule drug, so biosimilar risk is not applicable.
- Generic entry will depend on patent position, formulation equivalence, sterile manufacturing capability, and hospital workflow economics.
- The strongest follow-on product strategy is likely a technically improved formulation rather than a simple excipient replacement.
FAQs
Can Kimyrsa be diluted in normal saline?
No. The FDA prescribing information specifies 5% Dextrose Injection for dilution and warns against saline-containing solutions because of compatibility concerns.[1]
What is the role of mannitol in Kimyrsa?
Mannitol is listed as an inactive ingredient and likely contributes to the physical structure and stability of the lyophilized product. The FDA label does not disclose its precise quantitative formulation role.
Is Kimyrsa eligible for biosimilar competition?
No. Kimyrsa contains the small-molecule antibiotic oritavancin. Any follow-on product would use generic-drug or another applicable drug-approval pathway, not the biosimilar pathway.
Could a ready-to-use Kimyrsa bag extend market exclusivity?
A ready-to-use presentation could support separate formulation or delivery-system patent claims, but commercial exclusivity would depend on issued claims, FDA listing, validity, and enforcement. Packaging alone does not guarantee patent protection.
What is the highest-value formulation improvement for Kimyrsa?
Broader diluent compatibility is the clearest potential improvement because Kimyrsa's dextrose-only dilution requirement complicates hospital preparation. Longer stability and ready-to-administer packaging are other commercially relevant targets.
References
-
U.S. Food and Drug Administration. (2021). Kimyrsa (oritavancin) prescribing information. Melinta Therapeutics, LLC.
-
U.S. Food and Drug Administration. (2014). Orbactiv (oritavancin) prescribing information. The Medicines Company.
-
U.S. Food and Drug Administration. (2021, March 12). Kimyrsa approval letter, NDA 214429. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
